University of California Los Angeles (UCLA)
University / College
Location:
Los Angeles, CA,
United States (USA) (US)
ISNI: 0000000096326718
ROR: https://ror.org/046rm7j60
CTCF variants in 39 individuals with a variable neurodevelopmental disorder broaden the mutational and clinical spectrum (2019)
Konrad E, Nardini N, Caliebe A, Nagel I, Young D, Horvath G, Santoro SL, et al.
Journal article
National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism (2019)
Urato AC, Abi-Jaoude E, Abramson J, Alter H, Andrew LB, Antonuccio D, Bero L, et al.
Journal article, Letter
De novo variants in PAK1 lead to intellectual disability with macrocephaly and seizures (2019)
Horn S, Au M, Basel-Salmon L, Bayrak-Toydemir P, Chapin A, Cohen L, Elting MW, et al.
Journal article
Electron Diagnostics for Extreme High Brightness Nano-Blade Field Emission Cathodes (2019)
Lawler G, Sanwalka K, Zhuang Y, Yu V, Paschen T, Robles R, Williams O, et al.
Journal article, Review article
CTCF variants in 31 individuals with a variable neurodevelopmental disorder broaden the mutational and clinical spectrum (2019)
Konrad E, Nardini N, Blyth M, Prescott K, Bouman AM, Brilstra EH, Caliebe A, et al.
Conference contribution
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial (2019)
Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, et al.
Conference contribution
Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019)
Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al.
Conference contribution
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019)
Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al.
Conference contribution
Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study (2019)
Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, et al.
Journal article
Triaqua surface coordination complex on Co3O4(111) (2019)
Yan G, Wähler T, Schuster R, Schwarz M, Hohner C, Werner K, Libuda J, Sautet P
Conference contribution